CAR-T AS BRIDGE TO
HAPLO TRANSPLANT
For high-risk ALL, achieving MRD-negative remission with NexCAR19 is the first step — haploidentical stem cell transplant is the consolidation that turns remission into cure. Both are available in India at a fraction of Western costs.
analyticsAt a Glance
- check_circleHaplo-SCT uses a half-matched family donor — available to almost every patient
- check_circleRecommended for high-risk ALL: Ph+, MLL-rearranged, prior SCT relapse
- check_circleSequence: NexCAR19 → MRD-negative CR → haplo-SCT within 3–6 months
- check_circleCombined cost in India: $65,000–95,000 USD vs $700,000+ in the USA
Why Some ALL Patients Need Transplant After CAR-T
CAR-T achieves deep remissions in B-ALL — but for certain high-risk subgroups, the remission is not durable without further consolidation. Haploidentical SCT leverages the graft-versus-leukaemia (GvL) effect to provide long-term disease control.
“CAR-T opens the door. Haploidentical transplant is the lock that keeps it closed to relapse.”
Philadelphia Chromosome-Positive ALL
Ph+ ALL (BCR-ABL positive) is biologically aggressive and has a high relapse risk after CAR-T alone. TKI continuation (dasatinib or ponatinib) combined with NexCAR19 is used, followed by haplo-SCT consolidation for eligible patients in MRD-negative CR.
MLL-Rearranged and Complex Karyotype ALL
Mixed lineage leukaemia (MLL/KMT2A) rearrangements confer very high relapse risk. Complex karyotype ALL is similarly high-risk. Both are treated at Indian centres with CAR-T → transplant consolidation when an MRD-negative CR is achieved.
MRD-Positive Remission After CAR-T
Patients achieving morphological CR but remaining MRD-positive at Day 28 have a high risk of early relapse. Consolidative haplo-SCT is strongly recommended for MRD-positive remission, as the GvL effect may eradicate residual disease where CAR-T has not.
Relapse After Prior Autologous or Allogeneic SCT
Patients who relapsed after a prior allogeneic transplant can still receive NexCAR19 (provided adequate recovery from GvHD and adequate organ function). If a second haplo donor is available and performance status allows, a second allogeneic transplant after CAR-T remission may be considered at major Indian centres.
What Is Haploidentical Stem Cell Transplant?
Haploidentical SCT uses a donor who shares exactly half of the patient's HLA antigens — typically a biological parent, sibling, or child. Nearly every patient has at least one potential haplo donor.
50% HLA Match — Always a Family Donor
Every biological parent is haploidentical to their child (50% HLA match). Siblings have a 50% chance of being haplo and a 25% chance of being fully matched (MSD). This means virtually every patient has a readily available haplo donor — eliminating the donor search delay that affects matched unrelated donor (MUD) transplants.
Post-Transplant Cyclophosphamide: The Indian Standard
The PT-Cy-based haploidentical protocol (pioneered at Johns Hopkins, now the global standard) eliminates donor alloreactive T-cells after transplant — dramatically reducing GvHD without sacrificing the GvL effect. All major Indian haplo programmes use this approach.
The Full Pathway: NexCAR19 → Haplo-SCT Timeline
The complete CAR-T to transplant pathway in India typically spans 4–8 months from initial consultation to haplo-SCT completion.
- 1
CAR-T Evaluation + Leukapheresis
Eligibility confirmed. Leukapheresis performed at Tata Memorial or approved centre. NexCAR19 manufacturing begins.
- 2
Bridging Therapy (if needed)
Disease control chemotherapy during the 3–4 week manufacturing window for patients with rapidly progressive disease.
- 3
CAR-T Infusion + Recovery
Lymphodepletion → NexCAR19 infusion → 14–28 days inpatient monitoring. Day 28 MRD assessment confirms CR.
- 4
CR Confirmed — Transplant Planning Begins
MRD-negative CR confirmed. HLA typing of patient and family initiated. Haplo donor selected. Pre-transplant workup initiated.
- 5
Haplo-SCT Conditioning
Reduced-intensity or myeloablative conditioning with PT-Cy protocol begins. Patient admitted for transplant.
- 6
Haplo-SCT + Engraftment
Haplo donor stem cells infused. Engraftment typically 2–3 weeks. Post-transplant monitoring for GvHD, infection, and MRD.
Indian Centres Offering Both CAR-T and Haplo-SCT
Patients who require both NexCAR19 and haplo-SCT benefit from centres with integrated programmes — avoiding inter-hospital transfers and delays.
Tata Memorial Centre Mumbai
TMC is the highest-volume centre in India for both NexCAR19 and haploidentical SCT. The integration of ImmunoACT (on-campus) with TMC's BMT unit means the CAR-T → haplo pathway can be completed without transfer. International patients use the ACTREC campus for extended stays.
CMC Vellore (CMCH)
Christian Medical College Vellore runs one of India's most experienced haplo-SCT programmes and has an active CAR-T trials programme. Excellent for paediatric ALL cases and families preferring South India.
AIIMS New Delhi
AIIMS runs both investigational CAR-T trials and an established haplo-SCT programme. As a government hospital, AIIMS is significantly more cost-accessible for Indian patients, though availability for international patients should be confirmed.
Manipal Hospitals and Narayana Health
Both chains have established haplo-SCT programmes. Manipal also offers Kymriah for the CAR-T step. Narayana Health (Dr. Devi Shetty) is particularly known for paediatric haematology and transplant, with strong international patient support infrastructure.
Combined Pathway Cost: India vs USA
- $40–55KNexCAR19 All-In IndiaCAR-T manufacturing + lymphodepletion + inpatient monitoring at Tata Memorial.
- $25–40KHaplo-SCT IndiaHaploidentical stem cell transplant at TMC, CMC Vellore, or Narayana Health.
- $65–95KCombined Pathway IndiaFull CAR-T → haplo-SCT consolidation pathway — all-in cost in India.
- $700K+Same Pathway USAEstimated combined cost of CAR-T + allogeneic SCT in the United States.
More from the CAR-T India Resource Library
Explore the B-ALL programme, CAR-T timeline, and full cost guides.
- CAR-T Cell Therapy in India — Complete Guide
- CAR-T for B-Cell ALL in India: Paediatric and Adult Programmes
- The CAR-T Treatment Timeline in India: From Consultation to Discharge
- CAR-T Trials at AIIMS and CMC Vellore
- CAR-T Cost Breakdown in India: What International Patients Pay
- How to Access CAR-T Cell Therapy in India via CancerFax
Frequently Asked Questions: CAR-T + Haplo-SCT in India
Does the same hospital need to do both CAR-T and the transplant?
Not necessarily, but it is strongly preferred. Receiving both at the same centre (e.g., Tata Memorial) ensures continuity of care, shared records, and no delays in transition. However, CancerFax has coordinated cases where leukapheresis and CAR-T were performed at TMC and haplo-SCT was subsequently completed at a different centre closer to the patient's home country or support network. This requires careful coordination.
How long do family members need to be in India for the donor workup?
HLA typing is performed via a blood draw — family members can provide samples within 1–2 days of arriving in India, and results are available within 1–2 weeks. The actual stem cell donation (peripheral blood stem cell mobilisation and apheresis) requires the donor to be present for 5–7 days around the transplant date. Families do not need to remain in India continuously between CAR-T infusion and transplant.
What if a patient cannot tolerate a transplant after CAR-T?
If a patient achieves MRD-negative CR after NexCAR19 but cannot tolerate transplant due to organ dysfunction, performance status decline, or patient preference, close MRD surveillance is the alternative. The treating haematologist at TMC will discuss the risk-benefit profile of transplant vs surveillance for each individual case. Some standard-risk patients do well with surveillance alone.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Does Your ALL Case Need CAR-T + Transplant Consolidation?
CancerFax coordinates the full CAR-T → haplo-SCT pathway at a single Indian centre or across integrated programmes — including records review, eligibility, logistics, and family donor HLA typing.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.